Pacira Pharmaceuticals (PCRX) PT Raised to $24 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $36.39 --0%
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Rating Summary:
9 Buy, 19 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $24.00 (from $17.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Macquarie Upgrades Manila Electric Co. (MER:PM) (MAEOY) to Outperform
- Mohawk Industries (MHK) PT Raised to $147 at BofA Securities
- MediaTek Inc. (2454:TT) (MDTKF) PT Raised to TWD10,400 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
